Xenetic Biosciences, Inc. (XBIO)

Nasdaq: XBIO · Pharmaceutical Preparations · Framingham, MA · filing with the SEC since 2011

Full chart Alerts Compare

Grade5.6

◀ Past 4.8● Present 5.6▶ Future 6.1

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$3.0M+19.0%

Net income-$2.7M+32.3%

Earnings per share$-1.58+38.5%

Operating cash flow-$2.3M+18.8%

Cash$7.9M+27.9%

Debtn/a

Shareholders’ equity$7.4M+23.1%

Shares, diluted1,701,571+10.4%

Return on equity-36.3%

The recordfrom its filings

Filings in 202622

Newest filingNov 12 · 10-Q

Annual reportMar 12, 2026

Quarterly reportNov 12, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted1

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $3.0MNet income -$3.7MCash from operations -$2.3Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Sep 23, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Sep 18, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Sep 16, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 7, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Aug 6, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

May 29, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

May 14, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

May 13, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Xenetic Biosciences, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Framingham, MA.

Newest on the record

Quarterly report on Nov 12. Before it, large holder update, amended on Nov 12.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About XBIO

Xenetic Biosciences, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Framingham, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $3.0 million and a loss of $2.7 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersFramingham, MA

Business modelPre-revenue company

ExchangeNasdaq

Filing since2011

Fiscal year endsDec 31

SEC number (CIK)1534525

Peers on filePTN, BGMS, CNSP, RNXT

Who runs it

Financial performance

In fiscal 2025 Xenetic Biosciences’s revenue was $2.98 million, up 19.0% from $2.50 million the year before. It made a net loss of $2.68 million.

Annual report, filed Mar 12, 2026.

Financial statements

The grade

Xenetic Biosciences grades 5.6 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past4.8

● Present5.6

▶ Future6.1

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton XBIO · research, not advice